Meanwhile, Novartis seems to be leading the pack with TNO155, which has advanced to phase 2 testing as a monotherapy and is also in combination studies with Mirati's KRAS drug adagrasib.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback